Table 2.
T2D analysis reported by modeling based on sequence read abundance approach.
| SB/Bioinformatic Tool | Seq- Tech | Population | Associated genera with T2D | Reference |
|---|---|---|---|---|
| SparCC | Roche pyroseq 454 (V1-V3) 16S |
63 patients with T2D and obesity | Lachnospiraceae | 146 |
| SparCC | Illumina MiSeq (V3-V4) 16S 300 bp | 450 patients with T2D and hyperlipidemia | Blautia and Faecalibacterium spp. | 148 |
| SparCC | Illumina MiSeq WMS |
71 patients with T2D | Siphoviridae** | 121 |
| SparCC | Illumina MiSeq (V1-V3) 16S 300 bp |
106 patients with preT2D |
Barnesiella and Faecalibacterium |
126 |
| DESeq2 | Illumina MiSeq (V4) 16S 250 bp | 427 patients with IFG, IGT, IFG+IGT, T2D and NG* | Escherichia, Veillonella, Blautia and Anaerostipes | 170 |
| CoNet | Illumina HiSeq (V3-V4) 16S 250 bp |
83 patients with T2D and diabetic retinopathy | Anaerobiospirillum, Gardnerella, Cloacibacillus and Leptotrichia | 154 |
| SparCC | Illumina NovaSeq 6000 WMS and VLP |
74 patients with T2D | Escherichia phage, Geobacillus phage,and Lactobacillus phage | 120 |
*Normal Glucose Tolerance (NG), **A virus family.